Work

Abstract LB401: Bemcentinib and pembrolizumab may overcome exhaustive immune phenotypes in patients with treatment refractory lung adenocarcinoma and reveals a potential STAT3 bypass mechanism

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-lb401

Authors: Chia-Nung Hung, Daniel T. DeArmond, Jason M. Gauthier, Michael J. McGinity, Catherine Limboy, Meizhen Chen, Yajaira Esmeralda Mendoza-Plata, Jordy Urbina, Jacobo Louis Garza, Joel E. Michalek, David Micklem, Akil Jackson, Michael Chisamore, Tim H.M. Huang, Josephine A. Taverna

Institution: The University of Texas at San Antonio Health Science Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409820855

Cites:

Cited by: 1

Related to: 10